J-S. Frenel, Laurent Mathiot, Edith Bocorman, Alice Hervieu, E. Coquan, T. D. M. Rouge, E. Saâda-Bouzid, Renaud Sabatier, P. Lavaud, F. Legrand, C. Cropet, Emmanuelle Charaffe, Anthony Goncalves
{"title":"521 MOVIE试验中Durvalumab(D)+ Tremelimumab(T)+Metronomic Oral Vinorelbine(MOV)治疗复发性/转移性宫颈癌(RMCC)患者的安全性和有效性","authors":"J-S. Frenel, Laurent Mathiot, Edith Bocorman, Alice Hervieu, E. Coquan, T. D. M. Rouge, E. Saâda-Bouzid, Renaud Sabatier, P. Lavaud, F. Legrand, C. Cropet, Emmanuelle Charaffe, Anthony Goncalves","doi":"10.1136/ijgc-2024-esgo.14","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"189 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial\",\"authors\":\"J-S. Frenel, Laurent Mathiot, Edith Bocorman, Alice Hervieu, E. Coquan, T. D. M. Rouge, E. Saâda-Bouzid, Renaud Sabatier, P. Lavaud, F. Legrand, C. Cropet, Emmanuelle Charaffe, Anthony Goncalves\",\"doi\":\"10.1136/ijgc-2024-esgo.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"189 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial